Visionary Holdings receives Nasdaq notice over delayed annual filing

TORONTO - Visionary Holdings Inc. (NASDAQ:GV), a private education service provider with a market capitalization of $6.08 million and currently trading at $1.64, announced Saturday it received a notification from Nasdaq on August 5 indicating non-compliance with listing requirements due to its delayed annual report filing. The company’s shares have declined 34.8% year-to-date, reflecting ongoing operational challenges. InvestingPro data shows concerning financial health metrics, with an overall health score rated as "WEAK."

The company has not filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2025, violating Nasdaq Listing Rule 5250(c)(1), according to a press release statement.

The notification has no immediate impact on the trading of Visionary’s shares on the Nasdaq Capital Market. Following Nasdaq procedures, the company was given 60 days to submit a compliance plan, which it delivered on October 6. Visionary is currently awaiting Nasdaq’s review of its plan.

Visionary Holdings stated it is working with its independent auditor to complete the audit process and file the required annual report "as promptly as possible." The company expressed commitment to fulfilling its reporting obligations and maintaining its Nasdaq listing.

The Markham, Ontario-based firm operates in both private and public education sectors, providing academic programs to local and international students.

In other recent news, Visionary Holdings Inc. announced several strategic developments. The company has signed a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., securing worldwide rights to Yike’s stem cell technology. This agreement focuses on stem cell therapies for diabetes and immune diseases. Visionary Holdings also formed a joint venture with Jiangsu Yike Regenerative Medical Technology, creating Visionary Yike Stemcell Technologies Inc. to advance stem cell research and commercialization. Additionally, Visionary Holdings completed an equity adjustment to acquire a 51% controlling stake in Sikang (Guangzhou) Health Industry Investment Co., Ltd., which specializes in traditional Chinese medicine health preservation services. A strategic partnership was established with Qianxin Bocheng (Jiangsu) Technology Development Co., Ltd., aimed at developing the aesthetic treatment industry through various initiatives. Furthermore, Visionary Holdings entered into a partnership with Jiangsu Yike Regenerative Medicine for research in cellular rejuvenation and aesthetic treatment. These developments highlight Visionary Holdings’ ongoing efforts to expand its presence in the regenerative medicine and health industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.